Document Detail

Advanced/aggressive CTCL: improving the efficacy of treatment.
MedLine Citation:
PMID:  23149702     Owner:  NLM     Status:  Publisher    
Treatment regimens of patients with cutaneous T-cell lymphoma (CTCL) vary widely based on clinician preference and patient tolerance. Skin directed therapies are recommended for patients with early stage IA and IB MF, with combinations used in refractory cases. While no regimen has been proven to prolong survival in advanced stages, immunomodulatory regimens should be used initially to reduce the need for cytotoxic therapies. In more advanced stages of disease, treatment efforts should strive for palliation and improvement of quality of life. With many new therapies and strategies on the horizon, the future looks promising for CTCL patients.
P L Zinzani
Publication Detail:
Journal Detail:
Title:  Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia     Volume:  147     ISSN:  0392-0488     ISO Abbreviation:  G Ital Dermatol Venereol     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102852     Medline TA:  G Ital Dermatol Venereol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  563-572     Citation Subset:  -    
"L. e A. Seràgnoli" Institute of Hematology, University of Bologna, Bologna, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cutaneous peripheral T-cell lymphomas, unspecified/NOS and rare subtypes: a heterogeneous group of c...
Next Document:  Combination treatment in CTCL: the current role of bexarotene.